BIOCON — Biocon Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapMomentum Trap

Annual income statement for Biocon, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2019 March 31st	R2020 March 31st	R2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	Interim Report	Interim Report	ARS	ARS
Standards:	IAS	—	—	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	55,144	63,005	71,431	81,840	111,742
Cost of Revenue
Gross Profit	32,700	39,381	44,913	49,785	68,238
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	45,685	51,808	60,258	70,795	96,225
Operating Profit	9,459	11,197	11,173	11,045	15,517
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	12,149	12,149	10,677	9,831	8,971
Provision for Income Taxes
Net Income After Taxes	10,026	8,998	8,462	7,716	6,430
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	9,053	7,482	7,405	6,484	4,627
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,053	7,482	7,405	6,484	4,627
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	7.7	6.13	5.1	5.97	4.35
Dividends per Share